Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA. Read more – Press release
Authorization granted for a phase 2 clinical trial that aims to evaluate the technology developed by Hemerion. This study sponsored by Lille University Hopital (France) is multicentric with additional investigative center in Brussels (Erasme Hospital – Belgium).
The University of Lille’s Foundation awards the Hemerion Therapeutics founders for their scientific and entrepreuneurship involvement establishing a healthtech company.
The Hemerion’s founders enter the Eurasanté entrepreneurship program, an incubator dedicated to health start-up companies
Hemerion joins the Voisin Consulting Neighborhood program, a life science innovation center that offers tailored mentoring, coaching and global access to health tech entrepreneurs.
Hemerion is awarded during I-Lab innovation competition and granted to upgrade its lead product and better meet neurosurgeons needs.
Ground breaking preliminary results from the clinical study are published in the Journal of Neuro-Oncology. The Hemerion’s technology covered the 2018’s May issue. Read more